Skip to main navigation Skip to search Skip to main content

Myelotoxicity of Temozolomide Treatment in Patients with Glioblastoma Is It Time for a More Mechanistic Approach?

  • M.M. Said
  • , M.P.G. Broen
  • , E.L. Swart
  • , I.H. Bartelink
  • , M.C.M. Kouwenhoven*
  • *Corresponding author for this work

Research output: Contribution to journalEditorialAcademicpeer-review

Original languageEnglish
Article number1561
Number of pages7
JournalCancers
Volume15
Issue number5
DOIs
Publication statusPublished - 1 Mar 2023

Keywords

  • NEWLY-DIAGNOSED GLIOBLASTOMA
  • POPULATION PHARMACOKINETICS
  • MALIGNANT GLIOMA
  • STANDARD TREATMENT
  • AMERICAN SOCIETY
  • OPEN-LABEL
  • PHASE-II
  • MGMT
  • MYELOSUPPRESSION
  • RADIOTHERAPY

Cite this